Pfizer to stop selling Premarin hormone therapy in Canada
PFE•Pfizer will discontinue Premarin hormone therapy products in Canada after an internal review. Existing inventories of three tablet strengths are expected to last until about mid-2027, while no further batches of the cream will be supplied.
1. Canadian sales to end
Pfizer will stop selling Premarin vaginal cream and oral tablets in Canada following an internal review. The cream, used to treat menopause symptoms, has been in shortage since June, and no further batches will be supplied.
2. Tablet inventories remain
Existing inventories of Premarin tablets in 0.3 mg, 0.625 mg and 1.25 mg strengths are expected to last until about mid-2027, though they could run out sooner if demand increases. Pfizer said the decision was not related to new safety, efficacy or quality concerns and that other treatment options were available in Canada.
3. Other supply constraints
Some estradiol transdermal patch strengths made by Bayer and Sandoz are also in short supply in Canada, with intermittent shortages expected to continue until early 2027. Pfizer said the decision applies only to Canada; Premarin Intravenous, used in hospitals for abnormal uterine bleeding due to hormonal imbalance, is not affected.
